Ascent is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $11.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Ascent's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Xarelto | Bayer / Johnson & Johnson | Generic | 2025 | FDA-approved 14 May 2025 | ≈$5.3B |
| Xtandi | Astellas / Pfizer | Generic | 2027 | Filed with the FDA; settled 2025, terms confidential | ≈$6.0B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Ascent's share of it.
Ascent has FDA approval for Xarelto, with no US launch confirmed; and applications filed for Xtandi. It has settled with the brand owner over 1 drug. Of the 70 makers we follow, 31 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.